Immunovant's top three insider shareholders as of July 24, 2026 are Sciences Ltd. Roivant (Director, 113.32Mn shares), Peter Salzmann (Chief Executive Officer, 1.18Mn shares), Frank Torti (Director, 1.01Mn shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| George V Migausky | - | 137,251 | 0 | 03 Apr, 2025 |
| Andrew J. Fromkin | - | 99,732 | 0 | 09 Apr, 2026 |
| Mark S. Levine | Chief Legal Officer | 319,228 | 0 | 22 Nov, 2024 |
| Tiago Girao | Chief Financial Officer | 273,356 | 0 | 09 Apr, 2026 |
| Sciences Ltd. Roivant | - | 113,317,007 | 0 | 12 Dec, 2025 |
| Atul Pande | - | 116,731 | 0 | 09 Apr, 2026 |
| Frank Torti | - | 1,009,228 | 0 | 09 Apr, 2026 |
| Jake Bauer | - | 38,896 | 0 | 09 Apr, 2026 |
| Jay S Stout | Chief Technology Officer | 254,439 | 0 | 10 Apr, 2026 |
| Douglas J. Hughes | - | 134,653 | 0 | 09 Apr, 2026 |
| Tuyl Christopher Van | Chief Legal Officer | 183,231 | 0 | 10 Apr, 2026 |
| Julia G. Butchko | Chief Development Officer | 440,959 | 0 | 23 Aug, 2024 |
| Peter Salzmann | Chief Executive Officer | 1,178,191 | 0 | 17 Apr, 2025 |
| Eric Venker | Chief Executive Officer | 251,813 | 0 | 09 Apr, 2026 |
| William L. Macias | Chief Medical Officer | 357,353 | 0 | 21 Feb, 2025 |
| Eva Renee Barnett | Chief Financial Officer | 396,774 | 0 | 17 Apr, 2025 |
| Melanie Gloria | Chief Operating Officer | 245,222 | 0 | 10 Apr, 2026 |
| Michael Geffner | Chief Medical Officer | 217,958 | 0 | 24 Oct, 2025 |
| Robert Graham Susman | - | 38,896 | 0 | 09 Apr, 2026 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 23 Apr, 2026 | Jay S Stout | Common Stock | D | 2,754 | $29.62 | 251,685 | D | S |
| 23 Apr, 2026 | Tiago Girao | Common Stock | D | 25,760 | $29.62 | 247,596 | D | S |
| 08 Apr, 2026 | Jay S Stout | Common Stock | D | 8,614 | $24.83 | 255,957 | D | S |
| 08 Apr, 2026 | Melanie Gloria | Common Stock | D | 8,722 | $24.83 | 245,222 | D | S |
| 08 Apr, 2026 | Tuyl Christopher Van | Common Stock | D | 5,165 | $24.83 | 183,231 | D | S |
| 08 Apr, 2026 | Jay S Stout | Common Stock | D | 1,518 | $24.83 | 254,439 | D | S |
| 07 Apr, 2026 | Andrew J. Fromkin | Common Stock | A | 13,880 | $0.00 | 99,732 | D | A |
| 07 Apr, 2026 | Jay S Stout | Common Stock | A | 66,937 | $0.00 | 264,571 | D | A |
| 07 Apr, 2026 | Frank Torti | Common Stock | A | 174,189 | $0.00 | 1,009,228 | D | A |
| 07 Apr, 2026 | Atul Pande | Common Stock | A | 13,880 | $0.00 | 116,731 | D | A |
| 07 Apr, 2026 | Robert Graham Susman | Common Stock | A | 13,880 | $0.00 | 38,896 | D | A |
| 07 Apr, 2026 | Jake Bauer | Common Stock | A | 13,880 | $0.00 | 38,896 | D | A |
| 07 Apr, 2026 | Tiago Girao | Common Stock | A | 64,968 | $0.00 | 273,356 | D | A |
| 07 Apr, 2026 | Douglas J. Hughes | Common Stock | A | 13,880 | $0.00 | 134,653 | D | A |
| 07 Apr, 2026 | Tuyl Christopher Van | Common Stock | A | 41,343 | $0.00 | 188,396 | D | A |
| 07 Apr, 2026 | Eric Venker | Common Stock | A | 232,252 | $0.00 | 251,813 | D | A |
| 07 Apr, 2026 | Melanie Gloria | Common Stock | A | 83,671 | $0.00 | 253,944 | D | A |
| 07 Apr, 2026 | Tiago Girao | Stock Option (right to buy) | A | 94,002 | $0.00 | 94,002 | D | A |
| 07 Apr, 2026 | Robert Graham Susman | Stock Option (right to buy) | A | 7,061 | $0.00 | 7,061 | D | A |
| 07 Apr, 2026 | Douglas J. Hughes | Stock Option (right to buy) | A | 7,061 | $0.00 | 7,061 | D | A |